This report presented the results of patients with non-CNS malignancies treated in the UK proton overseas program. Four hundred and ninety-five patients were analyzed. 70.3% of patients were pediatric (<16 years). Rhabdomyosarcoma (RMS) and Ewing sarcoma were the most common diagnoses (42.6% and 34.1%). 51.3% of treated patients were for head and neck (H&N) tumors. At a median follow-up of 2.1 years, a 2-year survival rate of 88.3% and LC of 90.3% were reported. The grade 3 toxicity rate was 12.6%, with a median onset of 2.3 years. The conclusion of this report is that PBT demonstrates good local control, survival and acceptable toxicity rates for RMS and Ewing sarcoma.